{
  "id": "5e30f494fbd6abf43b000044",
  "type": "yesno",
  "question": "Is Selinexor effective for multiple myeloma?",
  "ideal_answer": "Yes, Selinexor is effective for multiple myeloma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31433920",
    "http://www.ncbi.nlm.nih.gov/pubmed/29203585",
    "http://www.ncbi.nlm.nih.gov/pubmed/31793336",
    "http://www.ncbi.nlm.nih.gov/pubmed/30352784",
    "http://www.ncbi.nlm.nih.gov/pubmed/31332020",
    "http://www.ncbi.nlm.nih.gov/pubmed/31429063",
    "http://www.ncbi.nlm.nih.gov/pubmed/29381435",
    "http://www.ncbi.nlm.nih.gov/pubmed/29610030",
    "http://www.ncbi.nlm.nih.gov/pubmed/29257139",
    "http://www.ncbi.nlm.nih.gov/pubmed/28668761",
    "http://www.ncbi.nlm.nih.gov/pubmed/29876006",
    "http://www.ncbi.nlm.nih.gov/pubmed/28596644"
  ],
  "snippets": [
    {
      "text": "Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29203585",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Based on these findings, we conclude that selinexor in combination with dexamethasone is active in heavily pretreated MM and propose a RP2D of 45 mg/m2 (80 mg) plus 20 mg dexamethasone given twice weekly. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29203585",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor, an Exportin-1 inhibitor, yielded promising results in quad- or penta-refractory MM including patients resistant to daratumumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29257139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381435",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381435",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor (KPT-330) is the first-in-human SINE compound. Early phase clinical trials have established the safety profile of this agent and have shown promising efficacy in combination with low-dose dexamethasone and other anti-MM agents. The combination of selinexor and dexamethasone has demonstrated activity in \"penta-refractory\" MM, (ie, MM refractory to the 5 most active anti-MM agents currently used in treatment).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29610030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found that DEX in combination with selinexor, an inhibitor of exportin-1 (XPO1) activity, synergistically inhibits the mTOR pathway and subsequently promotes cell death in MM cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29876006",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The current findings are consistent with the beneficial therapeutic outcome in patients with MM when treated with the combination of selinexor and DEX. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29876006",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30352784",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Selinexor is an oral inhibitor of the nuclear export protein exportin 1 (XPO1). Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) though suppression of NF\u03baB signaling and nuclear retention of tumor suppressor proteins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30352784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity also in patient cells resistant to bortezomib; hence, it is a promising target in MM patients. Hypoxia is known to mediate tumor progression and drug resistance (including bortezomib resistance) in MM cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor, used as a single agent, delayed tumor initiation and tumor progression, prolonging mice survival. In bortezomib-resistant xenografts, selinexor overcame drug resistance, significantly decreasing tumor burden and extending mice survival when combined with bortezomib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The responses seen with venetoclax in RRMM with t(11;14)(high BCL-2, low BCL-XL and MCL-1) and selinexor in penta-refractory myeloma which fulfills the FDA category of unmet need, opens up newer options for these patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596644",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma , despite an advisory panel 's concerns about the drug 's toxicity and the lack of randomized clinical data .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31332020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor ( in combination with dexamethasone ) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma ( RRMM) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31429063",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nSelinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31433920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31793336",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma (MM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31793336",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31429063",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}